Davion Healthcare Announces NASDAQ Trading Date and New Executive Leadership for Future Growth

Davion Healthcare Announces Significant Developments

In an exciting development for the healthcare sector, Davion Healthcare Plc has confirmed that it will begin trading on the Nasdaq Global Market on Thursday, October 22, 2026, under the ticker symbol "DAVI". This marks a pivotal moment for the next-generation digital healthcare company, which specializes in developing proprietary, non-invasive health monitoring technologies.

New Executive Leadership and Operational Structure

As part of this transition, Davion is introducing a new executive leadership team to steer the company toward its growth objectives. Glenn Williams, with over 35 years of experience in healthcare, has been appointed as the Chief Executive Officer (CEO), while Jeremy North takes on the role of Chief Operating Officer (COO). Their leadership comes at a crucial time as Davion prepares for its market debut, coinciding with Breast Cancer Awareness Month.

The newly established Operational Directorate will be at the helm of Davion's daily operations, which includes overseeing the commercialisation of its health monitoring solutions. This team comprises other senior executives focusing on aspects like international distribution and post-acquisition integration, ensuring the company aligns its strategies effectively.

Innovative Product Portfolios

Davion's flagship product, BreastCheck, is an FDA-registered, non-invasive breast health screening test designed to help individuals monitor their breast health conveniently at home. This product exemplifies Davion's commitment to preventive healthcare, allowing users to detect potential abnormalities through changes in breast temperature within just 15 minutes. Results can be accessed via a mobile app or online, reinforcing the company's mission to make health monitoring accessible outside traditional clinical settings.

In addition to BreastCheck, Davion has an expansive range of health monitoring technologies under development, including FootFlow for circulation monitoring, Testic for at-home testicular health evaluation, and ThermaDerm for detecting skin anomalies. These innovations reflect a broader commitment to providing comprehensive healthcare solutions targeting various preventative measures.

Growth Strategy and Financial Initiatives

Davion's growth strategy is twofold: it aims to drive revenue through the commercialization of its proprietary technologies and expand through strategic acquisitions within the healthcare market. In June 2026, the company adopted a direct commercialization approach to enhance its international manufacturing and distribution capabilities while identifying complementary businesses for acquisition purposes. This focus includes targeting companies capable of enhancing Davion's revenue and customer base or offering established distribution network capabilities in medical devices and healthcare services.

To support this strategy, Davion recently created Davion Healthcare Finance Ltd. and launched a £30 million five-year senior secured bond, designed specifically to fund upcoming acquisitions and strengthen its financial footing.

Leadership Insight and Future Vision

Incoming CEO Glenn Williams has voiced his excitement about leading Davion at a critical juncture, expressing his intentions to convert the company’s innovative capabilities into successful market launches and enhanced operational performance. Similarly, COO Jeremy North highlighted the strategic opportunities available for organic growth and acquisitions.

Previous CEO Jack Kaye is set to take the role of Chairman, where he will continue supporting the company's strategic vision alongside the newly appointed executives. This leadership transition is designed to foster a strong management structure that emphasizes growth and operational excellence in the rapidly evolving health technology landscape.

This announcement is expected to further boost Davion's profile in the healthcare community, providing invaluable tools for health monitoring and disease prevention, and helping the company to establish itself as a robust player on the global stage. As they pave the way for future innovations and market expansion, stakeholders and investors alike will be watching Davion closely as it embarks on this next chapter.

For further information about Davion Healthcare Plc and its breakthrough innovations in health monitoring, please visit www.davionhealthcare.com.